Class / Patent application number | Description | Number of patent applications / Date published |
514170500 | Mental disorder or mental illness (e.g., psychoses, etc.) affecting | 75 |
20100331258 | MEMORY IN SUBJECTS WITH MINI-MENTAL STATE EXAMINATION OF 24-26 - The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup. | 12-30-2010 |
20110039785 | POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF - The present invention is directed to polypeptide-nucleic acid conjugates. These conjugates can allow for targeted application of a therapeutic RNAi agent across the blood-brain barrier to treat, for example, a cancer, neurodegenerative disease, or lysosomal storage disorder. | 02-17-2011 |
20110086803 | PEPTIDES CONTAINING TRYPTOPHAN - The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45. | 04-14-2011 |
20110112033 | COGNITIVE ENHANCEMENT AND COGNITIVE THERAPY USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID - This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function. | 05-12-2011 |
20110172158 | TARGETS, METHODS, AND REAGENTS FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA - The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by performing the screens. | 07-14-2011 |
20110212895 | Treatment of Cognitive and Learning Impairment - Constitutive activators of Rho GTPases are useful in treating learning an cognitive disorders. | 09-01-2011 |
20110224144 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MENTAL DISORDERS - The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders. | 09-15-2011 |
20110257101 | CATECHOLAMINE REGULATED PROTEIN - A novel mammalian catecholamine-regulated protein called CRP40 is identified. This protein, and nucleic acid encoding same, is useful in methods of diagnosing and treating hypodopaminergic neurological disease, such as Parkinson's disease, multisystem atrophy, lewy body dementia, schizophrenia, and bipolar disease. | 10-20-2011 |
20110269688 | Genetic Alterations Associated with Schizophrenia and Methods of Use Thereof for the Diagnosis and Treatment of the Same - Compositions and methods for the detection and treatment of schizophrenia are provided. | 11-03-2011 |
20110288027 | TARGETS, METHODS, AND REAGENTS FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA - The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by performing the screens. | 11-24-2011 |
20110294739 | USE OF THE ENGRAILED HOMEODOMAIN PROTEIN AS ANXIOLYTIC - The present invention relates to the use of an Engrailed transcription factor for producing a medicament for anxiolytic purposes. | 12-01-2011 |
20110312892 | ANXIOLYTIC COMPOSITIONS CONTAINING ALPHA S1-CASEIN-DERIVED PEPTIDES - The invention relates to pharmaceutical compositions and food products containing peptides derived from the α | 12-22-2011 |
20120015882 | COMPOSITION FOR REGULATING AUTONOMIC NERVOUS ACTIVITY AND METHOD FOR REGULATING AUTONOMIC NERVE - The present invention provides an orally ingestible composition and a method for regulating an autonomic nervous activity. In particular, the present invention provides an orally ingestible composition capable of suppressing an increase in a sympathetic nervous activity, and an orally ingestible composition capable of promoting a parasympathetic nervous activity. The present invention is a composition for regulating an autonomic nervous activity, comprising, as an active ingredient, Tyr-Pro or a salt thereof. | 01-19-2012 |
20120021991 | USE OF A BOTULINUM NEUROTOXIN TO ALLEVIATE VARIOUS DISORDERS - Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin. | 01-26-2012 |
20120046232 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR - Disclosed are methods and compositions comprising mGluR modulators and procysteine drugs. The methods and compositions can be used to treat subjects with prior addiction in order to reduce drug use, drug seeking or relapse. | 02-23-2012 |
20120083449 | TREATMENT FOR ANXIETY - The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient. | 04-05-2012 |
20120142601 | Modified Peptides and Uses Thereof - The invention includes compounds that are useful in treating perioperative shivering or temperature spiking, lowering body temperature, treating psychosis or treating pain. The invention also includes methods for treating perioperative shivering or temperature spiking, lowering body temperature, treating psychosis or treating pain in a subject in need thereof. | 06-07-2012 |
20120165266 | METHOD FOR PREPARING GINTONIN, WHICH IS A NOVEL GLYCOLIPOPROETIN FROM PANAX GINSENG, AND GINTONIN, WHICH IS A NOVEL GLYCOLIPOPROTEIN, PREPARED BY THE METHOD - Disclosed are the novel glycolipoprotein gintonin isolated and identified from ginseng, a method for preparing the same, and uses thereof. Gintonin causes a transient increase in intracellular free Ca | 06-28-2012 |
20120277158 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS - The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder. | 11-01-2012 |
20130072437 | NEUREGULIN ISOFORMS,NEUREGULIN POLYPEPTIDES AND USES THEREOF - The present invention relates to new therapeutic and diagnostic uses of soluble neuregulin-1 isoforms and polypeptides, particularly neurological disorders. | 03-21-2013 |
20130130989 | EIF4E BINDING PEPTIDES - The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides. | 05-23-2013 |
20130150306 | MILK-BASED NUTRITIONAL COMPOSITIONS CONTAINING LACTOFERRIN AND USES THEREOF - The present disclosure relates to milk-based nutritional compositions comprising lactoferrin and/or a prebiotic component, wherein, when combined, the lactoferrin and prebiotic component may exhibit additive or synergistic beneficial effects on the health and development of a pediatric subject. The disclosure further relates to methods comprising the administration of said milk-based nutritional compositions to pediatric subjects. | 06-13-2013 |
20130217632 | Non-Natural Amino Acids - This invention relates in one aspect to non-natural desamino alkyl amino acid compounds, methods of making these compounds, and peptides containing these compounds. In one embodiment, the peptide is neurotensin (8-13) in which the N-terminus is an alpha-desamino, alpha-methyl-N,N-dimethyl-homolysine residue of the invention. | 08-22-2013 |
20130345141 | COMPOSITION FOR REGULATING CIRCADIAN RHYTHMS, COMPOSITION FOR DIAGNOSING CIRCADIAN RHYTHM DISORDERS AND DIAGNOSTIC KIT - The present invention relates to a composition for regulating circadian rhythms, a composition for diagnosing circadian rhythm disorders and a diagnostic kit, wherein the composition for regulating circadian rhythms comprises NQ peptides, C12orf39 genes, NQ peptides cDNA and the like, which relate to circadian regulation in vertebrates as main components. | 12-26-2013 |
20140107037 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS - The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine site partial agonist. | 04-17-2014 |
20140179613 | COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF - Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders. | 06-26-2014 |
20140235546 | Novel Peptide Inhibitors of Serotonin 5-HT2c Receptors:PTEN Interaction - The 5-HT 2C receptor is implicated in feeding, obesity, palatable food reward, metabolic disorders, drug addiction, anxiety, stress sensitivity, and depression. Embodiments of the invention are directed to modulation of the 5 -HT 2cR. Certain aspects are directed to therapies for the above referenced conditions. In certain aspects, therapeutic agents are identified that disrupt the 5-HT2cR:PTEN complex activating 5-HT2CR signaling. In certain aspects the complex is disrupted by a disrupter. The disrupter can be a peptide that displaces PTEN from the 5-HT 2cR:PTEN complex or inhibits the formation of the complex. | 08-21-2014 |
20140274906 | ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE - The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer. | 09-18-2014 |
20140323408 | METHOD OF INHIBITING DOPAMINERGIC CELL DEATH - Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications for reducing dopaminergic cell death. | 10-30-2014 |
20140342991 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, X-Pro-Pro-Y or a salt thereof, wherein X represent Val, Ile or Asn-Ile and Y represent Phe or Leu. | 11-20-2014 |
20150057231 | Use of Engrailed Proteins for Increasing Dopamine Synthesis by Dopaminergic Neurons - The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons | 02-26-2015 |
20150126455 | Novel Therapeutic Uses of Mu-Opiate Receptor Peptides - The present invention pertains to novel uses of endomorphine- | 05-07-2015 |
20150359847 | METHOD AND COMPOSITION FOR CONFERRING NEUROPROTECTION - The present invention relates to compositions and methods for neuroprotection. In particular, provided herein are compositions (for example, mesenchymal stem cell secretory factors) for alleviating and/or protecting against neuronal and neural stem cell damage (for example, resulting from traumatic brain injury), and methods of use thereof. | 12-17-2015 |
20160038567 | EIF4E BINDING PEPTIDES - The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides. | 02-11-2016 |
20160083428 | INHIBITORS OF THE Eph-A RECEPTOR AND USES THEREOF - Eph A receptor inhibitor peptides, and particularly Eph A4 receptor inhibitor peptides, are provided. The peptides comprise a sequence derived from the G-H loop of ephrin A4. Further, pharmaceutical compositions comprising said peptides and use thereof in treating, ameliorating or preventing diseases associated with memory formation are provided. | 03-24-2016 |
20160115197 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. | 04-28-2016 |
20160143992 | CLATHRIN THERAPEUTIC FOR PSYCHIATRIC and NEUROPSYCHIATRIC DISORDERS - The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating a psychiatric and/or neuropsychiatric disease, condition, or disorder, in vivo or in vitro. | 05-26-2016 |
514170600 | Anti-depressant or derivative affecting or utilizing | 38 |
20100249036 | METHOD FOR TREATING DEPRESSION - Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject. | 09-30-2010 |
20110021435 | COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASES - The present invention relates to a composition for preventing or treating neurological diseases, particularly brain diseases and improving cognitive functions by inhibiting apoptosis of neuronal cells and/or promoting generation of neuronal cells. The present invention provide a composition for preventing or treating a neurological disease, particularly brain disease, and a composition for improving a cognitive function, which comprises stanniocalcin 2 as an active ingredient. | 01-27-2011 |
20110098225 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) - The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role. | 04-28-2011 |
20110124571 | OPIORPHIN PEPTIDE DERIVATIVES AS POTENT INHIBITORS OF ENKEPHALIN-DEGRADING ECTOPEPTIDASES - The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases. | 05-26-2011 |
20110124572 | SYNDECAN-4 IS A REGULATOR OF RAC1-GTP - The present invention provides a method for modulating the activity of Rac1, comprising modifying the phosphorylation state of Ser179 in syndecan-4 through influencing the interaction between syndecan-4 and the guanin nucleotide exchange factor of Rac1 (RacGEF) named Tiam1 in a GTP-dependent manner. In particular, methods are provided for enhancing the epithelial phenotype of a cell and for initiating the polarization of a cell by increasing the de-phosphorylation of said Ser179 of syndecan-4, and for enhancing the migratory phenotype of a cell and for initiating the neuronal differentiation of a cell by increasing the phosphorylation of said Ser179 of syndecan-4. Polypeptides for use in modulating the activity of the small GTPase Rac are also provided, as well as a method for identifying an agent capable of indirectly modulating the activity of the small GTPase Rac 1. | 05-26-2011 |
20110136742 | ANTIDEPRESSANT PRODRUGS - The invention provides antidepressant prodrugs comprising an antidepressant conjugated to one or more amino acids. The invention also relates to pharmaceutical compositions comprising an antidepressant prodrug, and to methods of preparing and using the same. | 06-09-2011 |
20110178021 | OPIORPHIN FOR USE AS A PSYCHOSTIMULANT AGENT - The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and in children, depression, bipolar disease, dysthymic disorder and cyclothymic disorder. | 07-21-2011 |
20110183909 | Treatment of Mood and Anxiety Disorders - The invention relates to a selective inhibitor of Elk-1 or MSK-1 activation for use in the prevention and/or treatment of mood and anxiety disorders. | 07-28-2011 |
20110237515 | PEPTIDE DERIVED FROM NEUROTESIN RECEPTOR 3 AND USE THEREOF IN THE TREATMENT OF PSYCHIATRIC DISEASES - The invention relates to a peptide derived from neurotensin receptor 3 (NTSR3), and to the use thereof in the treatment of psychiatric diseases. The present invention particularly relates to the use of this peptide for producing a drug, such as an antidepressant. The peptide of the invention is characterized in that the sequence thereof is the attached SEQ ID No. 2. The present invention can be used in the fields of the pharmaceutical industry and particularly in the field of drug development for treating psychiatric diseases. The present invention can also be used in the development of a novel antidepressant. It can also be used for example, in the treatment of pain and inflammations. | 09-29-2011 |
20110288028 | AMYLIN AND AMYLIN AGONISTS FOR TREATING PSYCHIATRIC DISEASES AND DISORDERS - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 11-24-2011 |
20120122792 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS - S-t-butyl protected cysteine di-peptide analogs and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS). | 05-17-2012 |
20120122793 | S-Protected Cysteine Analogs and Related Compounds - S-protected cysteine analogs and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS). | 05-17-2012 |
20120129780 | LACTOFERRIN AND BRAIN HEALTH AND PROTECTION IN ADULTS - The present invention relates generally to the field of brain health, brain protection, maintenance of cognitive function, prevention of cognitive decline and cognitive disorders. Neuronal cells in the brain can be protected. Also cognitive performance can be increased. | 05-24-2012 |
20120135935 | GPR54 AGONISTS OR ANTAGONISTS FOR TREATMENT OF DISEASES PRESENTING BEHAVIORAL ABNORMALITIES - Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia | 05-31-2012 |
20120196809 | USE OF ICAM-1 FOR PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES - The present invention relates to a pharmaceutical composition for the prevention or treatment of neurological disorders, comprising an ICAM-1 (intercellular adhesion molecule-1) protein, or a fragment or a variant thereof as an active ingredient, which can increase the expression of neprilysin to remove amyloid-beta (Aβ), a cause of dementia, and is thus useful in preventing or treating a neurological disease including Alzheimer's disease. | 08-02-2012 |
20120208763 | NAP ALPHA-AMINOISOBUTYRIC ACID ANALOG WITH NEUROPROTECTIVE ACTIVITY - The invention relates to compositions and methods to confer protection on neurons. Peptides derived from the NAPVSIPQ (SEQ ID NO:4) peptide and including branched amino acids, such as alpha-aminoisobutyric acid, are included. Also included are methods of preventing and treating neurodegenerative disorders and damage caused by neurotoxic substances. | 08-16-2012 |
20120225821 | COMPOSITION FOR PREVENTING OR TREATING A SPINAL CORD INJURY - The present invention relates to a novel use of substance P. The substance P of the present invention exhibits effects of decreasing microglia activity, decreasing proinflammatory cytokines, inhibiting apoptosis, etc. The substance P of the present invention effectively treats degenerative central nervous system diseases or disorders such as a spinal cord injury caused by a traumatic injury (flexion injury, vertical compression injury, hyperextension injury, flexion-rotation injury) and by a non-traumatic injury (vascular dysfunction, arthritis, or degenerative arthritis), Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, depressive disorder, epilepsy, etc. | 09-06-2012 |
20120232015 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents - A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula Ia, or more particularly Formula Ib, or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described. | 09-13-2012 |
20120277159 | METHODS FOR TREATING DEPRESSION USING NCAM PEPTIDE MIMETICS - The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer from mental illness. | 11-01-2012 |
20120295852 | METHODS OF TREATING DEPRESSION AND OTHER RELATED DISEASES - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 11-22-2012 |
20130005662 | Methods of Treating Depression and Other Related Diseases - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 01-03-2013 |
20130035292 | NMDA Receptors Modulators and Uses Thereof - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 02-07-2013 |
20130035293 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE NEUROTRANSMISSION - The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling. | 02-07-2013 |
20130102538 | METHOD OF TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE PRESENILIN FUNCTION AND GAMMA-SECRETASE ACTIVITY - The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones that bind presenelin and thereby increase γ-secretase activity. | 04-25-2013 |
20130123186 | NEUROPROTECTION USING NAP-LIKE AND SAL-LIKE PEPTIDE MIMETICS - This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease. | 05-16-2013 |
20130150307 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disclosed is a method for decreasing depression in a patient by local administration of a botulinum neurotoxin to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles. | 06-13-2013 |
20130196923 | NOVEL PEPTIDES WHICH HAVE ANALGESIC EFFECTS AND WHICH INHIBIT ASIC CHANNELS - The present invention relates to novel isolated peptides which induce analgesia and which inhibit ASIC channels (Acid Sensing Ion Channels), to the polynucleotides encoding said peptides, and also to the pharmaceutical compositions, host cells and vectors comprising same. In particular, said peptides are isolated from the venom of the snake | 08-01-2013 |
20130203677 | BIOACTIVE PEPTIDE - The present invention provides a pharmaceutical or a food that comprises, as an active ingredient, at least one peptide selected from the group consisting of Val-Tyr-Leu-Pro-Arg, Tyr-Leu-Pro-Arg, and Leu-Pro-Arg, or an analog thereof. | 08-08-2013 |
20130210738 | COMPOSITION FOR PREVENTING AND TREATING NEUROLOGICAL DISEASES COMPRISING OSMOTIN - The present invention relates to a composition for preventing and treating neurological diseases, and more particularly to a composition for preventing and treating neurological diseases comprising osmotin, a health functional food composition for preventing and ameliorating neurological diseases comprising osmotin, and a method of preventing or treating neurological diseases by administering the composition. | 08-15-2013 |
20130288975 | Methods of Treating Depression and Other Related Diseases - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 10-31-2013 |
20130296248 | Methods of Treating Depression and Other Related Diseases - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 11-07-2013 |
20130310323 | Methods of Treating Depression and Other Related Diseases - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 11-21-2013 |
20130316954 | Methods of Treating Depression and Other Related Diseases - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 11-28-2013 |
20150051151 | Modified Kisspeptin Peptides and Uses Thereof - The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease. | 02-19-2015 |
20150315237 | NMDA Receptor Modulators and Uses Thereof - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 11-05-2015 |
20150329608 | OPIORPHIN FOR USE AS A PSYCHOSTIMULANT AGENT - The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and in children, depression, bipolar disease, dysthymic disorder and cyclothymic disorder. | 11-19-2015 |
20150352174 | USE OF GLYCYL GLUTAMINE AGAINST DEPRESSION - A prophylactic or therapeutic agent is provided for depression (including each subtype according to DSM-IV of depression) or anxiety by increasing the levels of serotonin in the brain includes administration of glycyl-glutamine or cyclo glycyl-glutamine, a derivative that could cross the blood-brain barrier and could be used in peripheral applications. | 12-10-2015 |
20160002292 | METHODS OF TREATING DEPRESSION AND OTHER RELATED DISEASES - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 01-07-2016 |